Antiplatelet drugs, or platelet agglutination inhibitors, are pharmaceuticals that play a vital role in reducing or preventing blood clotting by inhibiting platelet aggregation or adhesion. Blood clotting is a natural response that helps control external bleeding in case of injury. However, blood clots forming inside blood vessels can lead to severe complications by impeding blood flow. Hence, antiplatelet medications are therapeutically administered to inhibit clotting and restore average blood circulation promptly.
According to Data Bridge Market Research the Antiplatelet Drugs Market accounted for USD 2.05 billion in 2021, and expected to reach USD 3.82 billion by 2029. The market is expected to grow with a CAGR of 8.10% in the forecast period of 2022 to 2029.
“Rise in the incidences of cardiovascular diseases surge market demand”
The increasing prevalence of cardiovascular diseases is a crucial factor propelling the growth of the antiplatelet drug market. These conditions remain the primary cause of death in developed and developing countries. According to the Centers for Disease Control and Prevention (CDC), stroke and other cardiovascular disorders claim the lives of more than 800,000 people annually in the United States alone. The growing incidence of cardiovascular diseases widely using antiplatelet drugs significantly contributes to the market’s growth.
What restraints the growth of the antiplatelet drugs market?
“High cost associated with the antiplatelet drugs hinders the market’s growth”
The growth of the antiplatelet market is impeded due to the high cost associated with these drugs. The expensive nature of antiplatelet medications poses a challenge to the market's expansion. The affordability barrier limits patient access to these drugs, particularly in developing economies or regions with inadequate healthcare coverage. The cost restraints affect individual patients, healthcare systems, and insurers, creating a hurdle in achieving wider adoption and utilization of antiplatelet drugs, which restraints the market’s growth.
Segmentation: Antiplatelet Drugs Market
The antiplatelet drugs market is segmented on the basis of drug, indication, route of administration, end-users, and distribution channel.
- On the basis of drug, the antiplatelet drugs market has been segmented into Aspirin, clopidogrel, ticagrelor, prasugrel, and others.
- On the basis of indication, the antiplatelet drugs market has been segmented into myocardial infraction, percutaneous coronary interventions, arterial thrombosis, and others.
- On the basis of route of administration, the antiplatelet drugs market has been segmented into oral and injectable.
- On the basis of end-users, the antiplatelet drugs market has been segmented into hospitals, specialty clinics, homecare, and others.
- On the basis of distribution channel, the antiplatelet drugs market has been segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others.
Regional Insights: North America Dominates the Antiplatelet Drugs Market
North America dominates the antiplatelet drugs market owing to the increasing adoption of advanced technologies and the rising demand for targeted treatments for specific diseases. Furthermore, the market is propelled by the expanding presence of major key players and the upward trajectory of healthcare expenditure. These factors will contribute to further boosting the growth of the market.
Europe is expected to grow during the forecast period because of the escalating instances of myocardial infarction and the implementation of government initiatives. Additionally, the advancement of healthcare infrastructure will contribute to further propelling the market growth in this region.
To know more about the study visit, https://www.databridgemarketresearch.com/reports/global-antiplatelet-drugs-market
Recent Development
- In June 2021, Alfasigma announced the approval of the European license for bentracimab from PhaseBio. Bentracimab is a novel human monoclonal antibody fragment that has been shown to reverse the antiplatelet effects of Brilinta / Brilique in previous clinical tests.
The Prominent Key Players Operating in the Antiplatelet Drugs Market Include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France), Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- Bayer AG (Germany)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- Bristol-Myers Squibb Company (U.S.)
- Merck & Co., Inc. (U.S.)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- Otsuka America Pharmaceutical, Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- AbbVie Inc. (U.S.)
- Genentech, Inc.
- Baxter (U.S.)
- Bausch Health Companies Inc. (Canada)
Above are the key players covered in the report, to know about more and exhaustive list of antiplatelet drugs market companies contact, https://www.databridgemarketresearch.com/contact
Research Methodology: Global Antiplatelet Drugs Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
